ABSORICA LD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ABSORICA LD (ABSORICA LD).
Retinoid that reduces sebum production, normalizes follicular keratinization, and inhibits Propionibacterium acnes growth via modulation of gene expression.
| Metabolism | Hepatic metabolism via CYP450 enzymes (primarily CYP2C8, CYP3A4, and CYP2C9) to major metabolites: 4-oxo-isotretinoin and retinoic acid. |
| Excretion | Primarily renal, 65% as unchanged drug; 35% as metabolites. Fecal elimination accounts for less than 5%. |
| Half-life | Terminal elimination half-life is 21 hours (range 7–39 hours) for isotretinoin. Clinical context: Steady-state achieved after 5–7 days of dosing. |
| Protein binding | 99.9% bound to albumin. |
| Volume of Distribution | 4.5–6.0 L/kg, indicating extensive tissue distribution, particularly to sebaceous glands and skin. |
| Bioavailability | Oral: 25% (wide interindividual variation, enhanced when taken with high-fat meal). |
| Onset of Action | Oral: Clinical improvement in acne vulgaris typically observed within 4–8 weeks of initiating therapy. |
| Duration of Action | Therapeutic effect persists for several weeks to months after discontinuation; remission may be prolonged. Duration of therapy: 15–20 weeks for standard course. |
| Molecular Weight | 300.44 |
0.5-1 mg/kg/day orally divided twice daily for 4-5 months, max 2 mg/kg/day.
| Dosage form | CAPSULE |
| Renal impairment | No specific GFR-based dose adjustments established; contraindicated if severe renal impairment. |
| Liver impairment | Contraindicated in Child-Pugh class B and C; use with caution in class A with dose reduction. |
| Pediatric use | ≥12 years: 0.5-1 mg/kg/day divided twice daily for 4-5 months; max 2 mg/kg/day. |
| Geriatric use | Start at low end of dosing range; monitor for adverse effects. |
| 1st trimester | Contraindicated. Highly teratogenic; known to cause severe fetal abnormalities including CNS, cardiovascular, and facial defects. Pregnancy must be excluded before initiation, during therapy, and 1 month after discontinuation. |
| 2nd trimester | Contraindicated. Consistent risk of teratogenicity throughout pregnancy. |
| 3rd trimester | Contraindicated. Risk persists; no safe period during pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for ABSORICA LD (ABSORICA LD).
| Placental transfer | Isotretinoin crosses the placenta extensively. Fetal plasma levels are approximately 50% of maternal levels. The drug and its metabolites accumulate in fetal tissues, particularly the central nervous system and heart, leading to teratogenic effects. |
| Breastfeeding | Isotretinoin is lipophilic and may be excreted in breast milk. Potential for serious adverse effects in the nursing infant. Breastfeeding is not recommended during therapy and for at least 8 days after the last dose. |
■ FDA Black Box Warning
Isotretinoin must not be used by female patients who are or may become pregnant. There is an extremely high risk that severe birth defects will result if pregnancy occurs while taking any amount of isotretinoin, even for short periods. Potential for fetal harm, including spontaneous abortion or premature births.
| Serious Effects |
Pregnancy or potential pregnancy (females of childbearing potential must use two forms of contraception)Hypersensitivity to isotretinoin or any component of the formulationConcomitant use with tetracyclines (increased risk of pseudotumor cerebri)
| Precautions | Embryotoxicity, psychiatric disorders (depression, psychosis, aggression, suicidal ideation), pseudotumor cerebri, pancreatitis, hepatotoxicity, inflammatory bowel disease, hypertriglyceridemia, premature epiphyseal closure, decreased night vision, hypersensitivity reactions. |
| Food/Dietary | Take with a fatty meal or milk to enhance absorption. Avoid high-dose vitamin A supplements due to risk of hypervitaminosis A. Grapefruit juice may increase isotretinoin levels; avoid concurrent consumption. Alcohol may exacerbate hypertriglyceridemia and pancreatitis risk; limit or avoid. |
Loading safety data…
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | Isotretinoin (active ingredient of ABSORICA LD) is a known human teratogen with high risk of major fetal malformations (CNS, cardiovascular, craniofacial) and spontaneous abortion if exposure occurs during any trimester. First trimester exposure carries highest risk; second and third trimester exposure may cause fetal CNS abnormalities and preterm birth. Pregnancy is contraindicated. |
| Fetal Monitoring | Pregnancy testing: 2 negative urine or serum pregnancy tests with sensitivity >=25 mIU/mL before initiation, monthly during therapy, and 1 month after therapy discontinuation. Contraceptive counseling and use of two effective forms of contraception for at least 1 month before, during, and 1 month after therapy. IPLEDGE program registration and compliance monitoring. For fetal exposure: immediate pregnancy evaluation and referral to obstetrician. |
| Fertility Effects | Isotretinoin does not impair fertility in males or females in animal studies. However, due to teratogenicity, pregnancy must be avoided; no effect on spermatogenesis or oogenesis at therapeutic doses. |
| Clinical Pearls | ABSORICA LD is a high-dose isotretinoin formulation (35 mg/day) for severe recalcitrant nodular acne. Monitor for hypertriglyceridemia, transaminitis, and psychiatric symptoms. Counsel females of childbearing potential on strict contraception due to teratogenicity; ensure two negative pregnancy tests before starting. Do not prescribe concurrently with tetracyclines (risk of pseudotumor cerebri). Avoid blood donation during therapy and for 1 month after discontinuation. Most patients require 4-6 months of therapy. |
| Patient Advice | Do not become pregnant while taking this medicine; it can cause severe birth defects. Use two effective forms of contraception for at least 1 month before, during, and after treatment. · Avoid taking vitamin A or multivitamins containing vitamin A, as it may increase toxicity. · Report unexplained mood changes, depression, or suicidal thoughts immediately. · Minimize alcohol consumption; may increase risk of pancreatitis. · Expect temporary worsening of acne initially; continue medication as directed. · Do not donate blood during treatment and for 1 month after stopping. · Avoid prolonged sun exposure; use sunscreen as skin may be more sensitive. · Take with food or milk to improve absorption and reduce stomach upset. |